In this engaging discussion, Prof. Philippe Moreau from France, Dr. Robert Z Orlowski from MD Anderson, Dr. Noopur Raje from Massachusetts General, and Dr. Paul G Richardson delve into the complexities of managing multiple myeloma. They tackle innovative treatment strategies, including the use of CD38 antibodies, novel therapies, and the importance of minimal residual disease as a prognostic marker. The conversation also covers challenges in treating elderly patients, the role of CAR T-cell therapies, and the potential of the new BELLA drug in improving outcomes.
